



16 March 2020

Sydney, Australia

Update on Progress in Nyrada Programs

Highlights:

- **Two lead R&D programs progressing as planned and on-budget**
 - **Brain injury program leads to discovery of a new generation of more potent drug candidates**
 - **PCSK9 (cholesterol-lowering) program remains on-track towards goal of an oral, once a day tablet**
 - **Steps being taken to minimise any potential disruption to business operations by COVID-19**
-

Sydney, 16 March 2020: Nyrada Inc (ASX: NYR) provides an update on its two lead programs in brain injury and cholesterol-lowering.

Nyrada continues to make strong progress in both lead programs in line with its development schedule.

Brain Injury Program

The aim of this program is a drug to reduce secondary brain damage following head trauma and stroke in order to improve survivability and long-term patient outcomes.

Head trauma (motor vehicle accident, sporting injury, falls) and stroke are leading causes of hospital admissions and long-term rehabilitation service requirements. The Nyrada neuroprotectant program is focussed on secondary brain injury following the primary injury and a process of brain cell death known as excitotoxicity.

Nyrada is advancing a new generation of compounds with considerably greater potency in inhibiting what we believe is the key driver of secondary brain injury. The new drug compounds are novel and provide Nyrada with a strong competitive advantage in the design of an effective neuroprotectant drug, significantly broadening the Company's commercial opportunity. Details of this new family of compounds will be released shortly pursuant to a provisional patent being lodged.

Comment: Professor Gary Housley, Chair of the Nyrada Scientific Advisory Board and a recognised global contributor to neurological research, said: "I am delighted with the progress being made in this program. Progressive cellular excitotoxicity is recognised as a major mechanism that compounds mortality and long-term disability following stroke and brain trauma, and a drug which modulates this process to improve outcomes for these patients is long overdue. The recent progress builds our confidence that we will enter the clinic with a highly optimised drug."



Cholesterol-Lowering Program – PCSK9 inhibitor

This program aims to deliver a convenient and cost-effective drug that will help patients lower their LDL-cholesterol to a level considered low risk for developing cardiovascular disease. The drug works by inhibiting the function of a protein called PCSK9 that is central to the regulation of low-density cholesterol. The program remains on-track in its goal of identifying a lead candidate by mid-2020, a milestone that will trigger the path to human studies.

Comment: James Bonnar, Nyrada CEO, said, “The majority of patients taking statin therapy alone are unable to achieve their target LDL-cholesterol level and pharmaceutical companies are actively seeking new and better approaches. We and our advisors believe that a convenient and cost-effective “single pill” containing the Nyrada PCSK9 inhibitor and a generic statin will be an effective solution capable of capturing a share of a market currently worth approx. \$20 billion annually.”

General

Nyrada has a solid cash position having successfully raised \$8.5 million from its initial public offering in January 2020. In addition, the Company is actively pursuing a variety of non-dilutive funding and collaboration opportunities for the development of its product candidates.

The Company also confirms that its operations and supply chains currently remain unaffected by the COVID-19 situation, although the Company is taking precautionary steps to help quarantine its business from any global fall-out.

-ENDS-

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological and inflammatory diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Dr Graham Kelly, Non-Executive Director

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:



Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.